A new sector analysis modeling 3,036 therapeutic assets across 781 companies projects longevity biotech reaching $617 billion in annual global sales by 2045, with roughly $230 billion of risk-adjusted peak sales achievable through existing disease indications alone. Investment rose from $4.7 billion in 2024 to $18.4 billion in 2025, concentrated in fewer, larger deals, while more than 1,000 programs are already in human trials. Aging-targeted therapies are reaching patients via metabolic, cardiovascular and neurological pathways rather than waiting for a dedicated regulatory category.
Key Points
- Over 1,000 aging-targeted programs already in human clinical trials
- Investment quadrupled to $18.4 billion in 2025, concentrating in fewer deals
- Prevention remains smallest modeled segment despite upstream intervention evidence
Longevity Analysis
The commercial architecture forming around geroscience determines which interventions become available and when. Therapies modifying the processes behind metabolic decline, vascular deterioration and neurological aging are advancing through familiar disease approvals, meaning the first widely accessible tools for supporting repair capacity and energy metabolism will arrive labeled as treatments for specific conditions rather than as aging interventions. The modeling also exposes a structural asymmetry worth noting: reimbursement systems pay after damage occurs, leaving the highest-leverage window — removing accumulating burdens and correcting early signals in midlife — largely outside the funded market. Until validated aging biomarkers and accepted endpoints exist, individual measurement and disciplined daily practice remain the practical bridge.
Original published by Longevity.Technology, by Eleanor Garth.